Cencora, Inc. Surges as Pharma Distributor Outperforms Market

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a prominent player in pharmaceutical sourcing and distribution. The company boasts a market capitalization of approximately $54 billion and operates through its U.S. Healthcare Solutions and International Healthcare Solutions segments. Cencora provides an array of pharmaceutical supplies and healthcare services to various healthcare providers.

Stock Performance Compared to Market and Peers

This past year, Cencora has significantly outperformed the broader market. Over the last 52 weeks, COR stock has increased by 25.2%, and it has risen 24.2% year-to-date. In contrast, the S&P 500 Index ($SPX) has seen gains of 12.7% over the same period and a slight uptick of 8 basis points in 2025.

Focusing on industry benchmarks, Cencora has also outperformed the VanEck Pharmaceutical ETF (PPH), which has declined by 5.6% over the past year and by 1.8% in this year.

Impressive Q2 Results and Updated Guidance

Following the release of its strong Q2 results on May 7, Cencora’s stock prices jumped by 4.7%. The company’s extensive distribution network and comprehensive services continue to uphold its significance in the pharmaceutical supply chain. In Q2, revenues climbed 10.3% year-over-year to $75.5 billion, surpassing analysts’ expectations. Its adjusted net income also rose by 12.7% year-over-year, reaching $862.6 million. Additionally, the company’s share repurchase program reduced outstanding shares, causing a 16.3% increase in adjusted EPS to $4.42, beating consensus estimates by 8.3%.

In response to these results, Cencora raised its full-year adjusted EPS guidance from a previous range of $15.30 to $15.60 to a new range of $15.70 to $15.95, which has instilled greater confidence among investors.

Future Projections and Analyst Ratings

For fiscal 2025, which ends in September, analysts anticipate a 15.1% increase in adjusted EPS to $15.84. Notably, Cencora has a strong track record, having exceeded bottom-line estimates in each of the last four quarters.

Among 15 analysts covering the COR stock, the consensus rating is a “Strong Buy,” comprising 11 “Strong Buys” and four “Holds.” This sentiment has remained steady in recent months.

On May 8, Baird analyst David Rodgers reaffirmed an “Outperform” rating on COR, raising the price target from $314 to $350. Currently, the average price target for Cencora stands at $318, indicating a 14% premium over current price levels. The highest target of $355 suggests a potential upside of 27.2%.

On the date of publication, Aditya Sarawgi did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. For more information, please view the Barchart Disclosure Policy here.

More news updates are available.

The views expressed in this article are those of the author and do not necessarily reflect those of Nasdaq, Inc.